Urinary and biliary excretion of aluminoxamine and ferrioxamine in dogs with various renal function  by D'Haese, Patrick C. et al.
Kidney International, Vol. 45 (1994), PP. 76-84
Urinary and biliary excretion of aluminoxamine and
ferrioxamine in dogs with various renal function
PATRICK C. D'HAESE, LUDWIG V. LAMBERTS, GERT A. VERPOOTEN,
WOUTER VANEERDEWEG, ANGELIKA JURGENS, SAHAK ARAKELIAN, Ait BABLOYAN,
PANAGIOTIS DIGENIS, WIEBREN TJALMA, and MARC E. DE BROE
Department of Nephrology-Hypertension, University of Antwerp, Antwerp, Belgium; Department of Pediatric Urology, Erevan, Armenia; and
Renal Unit, Sismanoglion General Hospital, Athens, Greece
Urinary and biliary excretion of alumlnoxamine and ferrioxamine in
dogs with various renal function. We assessed the pharmacokinetics of
aluminoxanune and ferrioxamine in dogs with sustained intermittent
bile duct ligation and either normal renal function or stable chronic
renal failure. A first group of male beagle dogs were given aluminox-
amme and ferrioxamine, while a second group received desferriox-
amine after loading them with iron and aluminum. Only minute amounts
of ferrioxamine and aluminoxamine were found in the bile after admin-
istration of these compounds. The distribution volume of aluminox-
amine and ferrioxamine appeared to be confined to the extracellular
space and their renal excretion correlated with renal function. Admin-
istration of desferrioxamine to iron and aluminum-loaded dogs resulted
in an increased biliary ferrioxamine but negligible alummoxamine
excretion. Renal clearance of the in vivo formed ferrioxamine and
aluminoxamine in this group strongly correlated with renal function.
Our observations indicate that biliary excretion of intravenously admin-
istered ferrioxamine and aluminoxamine is negligible even in renal
failure. The data presented in this study provide indirect evidence that
desferrioxamine administration to iron- and aluminum-loaded dogs
results in the intra-hepatic formation of ferrioxamine which is partly
excreted in the bile. Biliary excretion of aluminoxamine after desferri-
oxamine administration remained negligible.
Desferrioxamine (DESFERAL®), a trihydroxamic acid ob-
tained from isolates of an actinomycete, Streptomyces pilosus,
effectively chelates trivalent ions such as iron (stability con-
stant; Ks = 1031). Therefore, it was introduced in 1963 as an
iron chelating agent in patients with chronic iron overload.
Although it has been known for some time that desferrioxamine
forms a complex with aluminum (Ks = 1022) also, it is only
since 1980, following the observation of Ackrill et a! [1] that the
chelator has been used in the therapy of aluminum overload in
dialysis patients.
Desferrioxamine displays rather complicated physicochemi-
cal characteristics [2]. Unchelated desferrioxamine is a straight
chained lipophilic molecule penetrating plasma membranes and
undergoing metabolic breakdown. In contact with either iron or
aluminum, it twines itself around the metal to form stable
hydrophiic complexes.
Minor and major side effects have been observed during
desferrioxamine treatment, particularly in dialysis patients.
These include allergic skin reactions [3], ocular and auditory
neurotoxicity [4], hypotension [5], thrombocytopenia [6], acute
changes in renal function [7] and gastrointestinal disturbances
[5]. Exacerbation of aluminum encephalopathy has been re-
ported during the early stages of desferrioxamine treatment [8,
9]. The iron-desferrioxamine complex (ferrioxamine) both pro-
vides a source of iron and stimulates the growth of certain
microorganisms of the Rhizopus class, and there is a strong
correlation between treatment with desferrioxamine and the
development of fatal muconnycosis [10, 11].
Only scarce information dealing with the kinetics of desfer-
rioxamine and its chelated compounds is found in the literature.
This is primarily due to the lack until recently [12] of accurate
and sensitive methods for assaying desferrioxamine and its iron
and aluminum-chelated substances.
In a previous study [13] we examined the kinetics of the
chelator and its chelated compounds, ferrioxamine and alumi-
noxamine in dialysis patients. We found that the serum half-life
(t½) of ferrioxamine was increased in dialysis patients, partic-
ularly those with iron overload combined with liver disease.
Moreover, as have others [14, 15], we noted that whereas serum
aluminoxamine remained stable during the inter-dialytic period
indicating the unique role of the kidney in the elimination of this
compound, ferrioxamine levels decreased during this time
interval. These observations prompted us to suggest that in
contrast to aluminoxamine, the liver plays a role in the elimi-
nation of ferrioxamine. To test this hypothesis, kinetics of
aluminoxamine and ferrioxamine were studied in dogs with
external biliary derivation and either normal renal function or
reduced renal mass [16]; the dogs received either (i) aluminox-
amine and femoxamine or (ii) desferrioxamine after iron and
aluminum loading.
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Pharmacokinetics of desferrioxamine, ferrioxamine and alu-
minoxamine were studied in 16 adult male beagle dogs. The
set-up of the study is schematically presented in Figure 1.
Group I dogs (N = 8) received (i.v.) aluminoxamine and
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Fig. 1. Study set-up and sampling points (V
and V). A reduction in renal mass was
induced in 4 dogs of Group I and 5 dogs of
Group II. The inset shows the bile duct
ligation in the dog allowing sustained
intermittent bile collection during at least 3
weeks. Abbreviations are: AlO,
aluminoxamine; FO, ferrioxamine; DFO,
desferrioxamine.
ferrioxamine. Group II dogs (N = 8) were pre-loaded with iron
and aluminum and then received desferrioxamine (i.v.). Renal
function in both groups varied from normal (Group I: N = 4;
Group II: N = 2) to severe chronic renal failure (Table 1). In
dogs with normal renal function the GFR as determined by
measurement of the Cr-EDTA clearance was 71.9 13.1
mllmin. Dogs were fed a standard chow (Doko, Ghent, Bel-
gium) with free access to tap water before and during the
experimental period. Time intervals for sample collection are
presented in Figure 1. Venipuncture, sampling of bile and urine
and storage of these specimen were done following the proce-
dures described elsewhere [17]. Venipuncture was done using a
winged infusion set (Viggo-Spectramed, JMS, Singapore).
Blood and bile samples were collected and stored in 10-mi
sterile syringes (Monovette, Sarstedt, NUmbrecht, Germany).
No anticoagulant was used to reduce the risk for iron and/or
aluminum contamination on the one hand, and to prevent
interference with the chelated products on the other. Urine
samples were collected by catheterization of the urinary blad-
der and stored in stoppered polystyrene containers. Storage of
samples was done at —20 or —80°C.
Canine remnant kidney model
A stable chronic renal failure was induced in four dogs of
group I (E-H; Table 1) and in five dogs of group II (D-H; Table
1) according to the method described by Vaneerdeweg et al
[16]. In summary, with this procedure 50 to 60% of the cortex of
the left kidney is resected followed by nephrectomy of the right
kidney one week later. This surgical intervention was per-
formed under anesthesia induced by FENTANYL (Janssen
Pharmaceutica, Beerse, Belgium) and 20 mg/kg Pentobarbital
(NEMBUTAL®; Abbott, Chicago, Illinois, USA). After intu-
bation of the trachea, lungs were normoventilated with an
02/N20 mixture. Anesthesia was maintained by 0.5 to 1.0%
Enflurane (ETHRANE®; Abott). A stable chronic renal failure
was obtained two months after surgery, and was maintained
during a 9 to 12 month time period.
16 dogs (conscious)
renal Jailure
bile drain
Group 1
PC, AIC adm.
Group 2
Fe, Al loading
DFO
adm.
8 dogs
30 minutes
administration
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_________
4 4 4
minutes hours
V blood, urine and bile sample
V blood sample
bile drain
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Table 1. Individual serum creatinine and mean SD body weight
and biochemical blood values of dogs of Group I and Group II
Dog Group I Group II
Serum creatinine mg/dl A
B
C
D
E
F
G
H
0.50k
0.70k
0.83a
0.95
2.18
2.20
4.10
6.30
0.60k
0.90a
171b
2.79
2.90
2.90
3.00
9.62
Body weight kg 12.8 3.0 13.1 2.9
Calcium mg/dl 9.7 1.1 10.3 1.3
Phosphorous mgldl 6.8 3.0 7.0 2.6
Bilirubin total/direct 0. 1/0.01 0.1/0.01
mg/dl
Alkaline phosphatase 68 65 97 92
U/liter
Data of group I versus group II are not significantly different. Normal
values as determined from ongoing screenings in 1783 normal Beagle
dogs (Janssen Pharmaceutica, Beerse, Belgium) are: creatinine 0.82
0.09 mgldl; calcium 10.9 0.5 mg/dl; phosphorous 5.7 1.1 mg/dl;
alkaline phosphatase 125 50 U/liter; total bilirubin 0.12 0.04 mg/dl.
a Dogs that are considered to have normal renal function
b This dog did not undergo kidney tissue resection, however, at the
onset of the experiment appeared to have developed mild renal failure,
the etiology of which we were not able to define
Bile collection
Four days prior to sampling, dogs with normal renal function
as well as those with renal failure underwent an operation
allowing sustained and intermittent bile sampling (Fig. 1) [18].
Dogs were anesthetized as described above. With this proce-
dure the common bile duct was isolated and distally ligated. A
Pedinielli PVC catheter (Porges, Sarlat, France) was introduced
and fixed into the bile duct, taking care not to obstruct any of
the hepatic ducts. The catheter was brought subcutaneously
under the skin incision and repositioned into the abdomen,
where it was fixed into the duodenum. At the time of sampling,
the skin incision was reopened under local anesthesia. The
catheter was cut in order to collect the bile flowing from the bile
duct. At the end of the experiment, a silicon tube was slipped
over the catheter to reconnect both ends and the skin was
closed again.
Aluminoxamine and ferrioxamine administration
Aluminoxamine and ferrioxamine were freshly prepared by
mixing equivalent amounts of desferrioxamine with aluminum
or iron. Theoretically, 100 g of desferrioxamine binds 4.12 g of
aluminum or 8.54 g of iron. As such, 20.6 mg of aluminum
(corresponding with 184.3 mg of A1C13 . 6H20) or 42.7 mg of
iron (corresponding with 206.2 mg of FeC!3 . 6H20) were each
solubiized in 5 ml of a 5% glucose solution. The corresponding
solutions were then transferred to a flacon containing 500 mg of
desfemoxamine. Solutions were mixed for one hour on a rotary
mixer to allow complete formation of aluminoxamine and
ferrioxamine, respectively. Six hundred and seventy d of the
aluminoxamine solution and 640 d of the ferrioxamine solution
were then added to 30 ml of a 5% glucose solution in water. This
solution thus contained 60 mg of both compounds and was
administered i.v. during 30 minutes to dogs of group I.
Iron and aluminum loading
Iron loading was performed in dogs of group II by i.v.
administration of 150 mg iron per day as dextran iron (Fisons
Pharmaceuticals, Leicesterhire, UK). Aluminum loading was
done by i.v. administration of 30 mg aluminum per day as
Aid3 6H20. Both compounds were solubilized in 50 ml of
0.85% saline and administered simultaneously every two days
for 10 days (that is, 5 injections). The kinetic study protocol was
then started three days after completion of aluminum and iron
loading.
Desferrioxamine administration
Dogs of group II received 200 mg (305 mol) of desferriox-
amine (DESFERAL®; Ciba-Geigy, Basle, Switzerland) in 30 ml
of a 5% glucose solution in water by a 30 minute i.v. infusion.
Chemical analysis
Desferrioxamine, aluminoxamine and ferrioxamine were de-
termined by Zeeman atomic absorption spectrometry using a
method we previously described [12]. With this method the
mean SD recoveries of aluminoxamine and ferrioxamine after
extraction were 98.3 2.7% and 101 3.7%, respectively. The
sensitivity was 45 pgIO.0044 Abs sec for aluminum and 10
pgIO.0044 Abs sec for iron, corresponding with detection
limits of 0.22 &molIliter for aluminoxamine and 0.06 psnollliter
for desferrioxamine and fernoxamine, respectively.
Measurement of aluminum and iron in tissues was done by
electrothermal atomic absorption spectrometry using our pre-
viously described methods [17, 19].
In addition, the following blood parameters were determined:
serum creatinine (kinetic Jaffd method; assay kit; J.T. Baker,
The Netherlands), direct and total biirubin [dichlorophenyldi-
azonium (DPD) method; T-BiL assay kit; Boehringer Mann-
heim, Germany], calcium (colorimetric method; Ca-assay kit;
bio Mérieux, France), inorganic phosphate (enzymatic colori-
metric method; PHOS assay kit; Boehringer Mannheim) and
alkaline phosphatase (enzymatic method [20]).
Data analysis
The rate constant of elimination (p) for ferrioxamine and
aluminoxamine was determined by least squares non-linear
regression analysis of the post-distribution phase of the serum
concentration-time curve, using the BMDP Statistical Software
[21]. The corresponding serum t½ was calculated as 0.693/p.
The area under the concentration-time curve (AUC) was deter-
mined with the trapezoidal rule. Renal clearances were calcu-
lated by dividing the cumulative amount of the respective
compounds in the urine by the corresponding AUC values.
Data are expressed as mean SD, except the serum t'/2 values
for which the harmonic mean (range) is reported.
The paired t-test was used for comparison of distribution
volumes, renal clearance and cumulative renal and biliary
excretion of aluminoxamine versus ferrioxamine. We used the
unpaired t-test to compare data on body weight, calcium,
phosphorus, alkaline phosphatase and bilirubin concentrations,
peak serum level of aluminoxamine and ferrioxamine (Cm)
and biliary excretion of these compounds of group I versus
group II. Because of the limited sample size, the Mann-Whitney
U-test was used to compare serum tV2 and renal clearance of
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Table 2. Comparison of pharmacokinetic data of aluminoxamine
versus femoxamine after aluminoxamine/ferrioxamine administration
(Group I)
70
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Parameter Aluminoxamine Femoxamine P
Cmax° pmol/liler 24.7 8.0 29.3 10.1 NS
Serum t'/2 vs. Y = 126.7X —93.4 Y = 102.6X —42.1 NS
serum
creatinine
AUC vs. serum
r = 0.9483
Y = 4.06X — 1.91
r = 0.9891
Y = 4.64X - 1.05 NS
creatinine
tI/2b miii
r = 0.9395
33.7 (29.5 — 37.8)
r = 0.9566
37.4 (23.9 — 51.5) NS
Relative 0.34 0.14 0.29 0.14 NS
distribution
volume liter/kg
Cumulative renal 52.4 16.7 57.0 21.9 NS
excretion
.unol/O—24 hr
Cumulative renal 51.3 16.4 58.2 22.0 NS
excretion/0.-24
hr/total dose %
Renal clearance Y = 37.69X — 4.49 Y = 33.95X — 7.27 NS
vs. 1/serum
creatinine
Renal clearancee
r = 0.9541
41.0 18.8
r 0.9652
34.4 22.6 NS
mi/mu
Cumulative biliary 0.19 0.20 0.36 0.32 NS
excretion
ismol/O—24
hours
Cumulative biliary 0.19 0.20 0.37 0.33 NS
excretion/0—24
hr/total dose %
e 0
_L
• 4
E
a)3
a)
C)2
C
E
Ca
1
.g
a)
Oo 0 0 0
____ I,,,. I
0.5 1 1.5 2 4 .
E
a)30C(a
= 37.69x 2 0
r=0.9541
•
x10C
E
a 00 0 0 0 .I,,,, .1.... I
0.5 1 1.5 2
.
.
a Peak serum level of ferrioxamme and aluminoxamine
b Harmonic mean
C Dogs with normal function (N = 4)
ferrioxamine versus aluminoxamine in dogs with normal renal
function, and Cm levels of these compounds in dogs with
normal renal function versus those with renal failure. Compar-
ison of slopes and intercepts of linear regression curves was
done by analysis of variance of regression coefficients over
groups. A P value < 0.05 was considered to be significant at a
two-tailed level.
Results
Table 1 summarizes the biochemical characteristics of dogs
of groups I and II. Data do not differ significantly between
groups I and II and show the presence and characteristics of a
chronic renal failure, the absence of metabolic bone disease,
and impairment of renal function. In contrast to Henry et al
[221, hypercalcemia was not noted after aluminum loading.
Aluminoxamine/ferrioxamine administration
In group I (Table 2) peak serum levels of aluminoxamine and
ferrioxamine were 24.7 8.0 mo1/liter and 29.3 10.1
mol/liter (NS), respectively. Peak levels of both compounds
were not significantly different in dogs with normal renal
function as compared to those with renal failure [23.4 5.8
zmolJliter vs. 26.1 10.5 jsmollliter (NS) for aluminoxamine
and 26.2 13.5 smo1/liter vs. 32.0 13.5 smol/liter (NS) for
ferrioxamine].
1/Serum creatinine, dl/mg
Fig. 2. Renal (• •) and hepatic (0) clearance of ferrioxamine (A)
and aluminoxamine (B) in dogs with various renal functions after i.v.
administration of the compounds.
A linear correlation existed between the serum creatinine
concentration and the serum t½ of aluminoxamine (r = 0.9483)
and ferrioxamine (r = 0.9891), as well as between the serum
creatinine concentration and the AUC of aluminoxamine (r =
0.9395) and ferrioxamine (r = 0.9566; Table 2). In dogs with
normal renal function (serum creatinine < 1.2 mg/dl) serum t½
of aluminoxamine was 33.7 (29.5 to 37.8) minutes, compared to
37.4 (23.9 to 51.5) minutes (NS) for ferrioxamine. Relative
distribution volumes were not significantly different, being 0.34
0.14 liter/kg for aluminoxamine versus 0.29 0.14 liter/kg for
ferrioxamine.
Respectively, 51.3 16.4% and 58.2 22.0% (NS) of the
chelates were recovered in the urine within 24 hours following
administration of 60 mg of aluminoxamine and ferrioxamine.
The cumulative renal excretion of aluminoxamine and ferriox-
amine over 24 hours did not correlate significantly with the
serum creatinine level (r —0.65; P = 0.081 and r = —0.52; P
= 0.186, respectively).
A linear correlation existed between the renal clearance of
aluminoxamine (r = 0.9541) and ferrioxamine (r = 0.9652) and
the reciprocal value of serum creatinine (Table 2). As indicated
by the slopes of the equations, renal clearance of aluminoxa-
mine and ferrioxamine did not differ significantly (Fig. 2). Mean
renal clearance of aluminoxamine and ferrioxamine in dogs with
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Group I(N=8) Group II(N=8)
Liver iron 227 33 2084 1044
xg/g wet WI (203—250) (901—3958)
Liver aluminum 2.5 2.7 267 287
g/g wet WI (0.6—4.4) (50—780)
Bone iron 96.8 61.0 301 55
jgfg wet WI (42—150) (227—361)
Bone aluminum 1.4 0.14 22 9.6
jxg/g wet WI (1.2—1.5) (12.3—33.0)
Parameter Aluminoxamine Ferrioxamine P
Cmaxa unol/1iter 10.8 5.2 11.8 4.5 NS
Serum t½ vs. serum Y = 27.56X + 102 Y = 26.99X + 196 NS
creatinine
AUC vs. serum
r = 0.7721
Y = 0.SOX + 1.61
r = 0.6246
Y = 0.59X + 0.37 NS
creatinine
Renal clearance vs.
r = 0.8156
Y = ll.23X + 3.25
r = 0.9216
Y = 12.29X + 1.47 NS
1/serum creatinine
Cumulative biliary
r = 0.9353
0.21 0.13
r = 0.9486
4.89 3.12 0.0022
excretion mol/0-
24 hours
a Peak serum level of fenioxamine and aluminoxamine
normal renal function was 41.0 18.8 and 34.4 22.6 mllmin
(NS), respectively.
When compared to their renal excretion, the biliary elimina-
tion of aluminoxamine and ferrioxamine was negligible and
accounted for only 0.19 0.20% and 0.37 0.33% (NS) of the
total administered dose of aluminoxamine and ferrioxamine,
respectively. As shown in Figure 2 biliary elimination of the
chelates was not influenced by the level of renal function.
Desferrioxamine administration
When compared to the unloaded dogs (that is, dogs of group
I), in group II dogs the efficiency of the i.v. iron and aluminum
loading was demonstrated by a 9.2-fold increase in the hepatic
iron content and a 107- and 15.7-fold increase in the hepatic and
bone aluminum content, respectively (Table 3). Body weight
was not affected by iron and aluminum loading [mean weight
SDoflron-andaluminum-loadeddogs 13.1 2.9 kg vs. 12.8
3.0 kg (NS) for the unloaded animals (Table 1)]. The results of
iron and aluminum loading were not related to the level of renal
function as indicated by the lack of a significant correlation
between the serum creatinine concentration and the (i) liver
aluminum (r = —0.2634, NS), (ii) bone aluminum (r = —0. 1073,
NS), and (iii) liver iron (r =
—0.1265, NS).
Peak serum ferrioxamine and aluminoxamine levels did not
differ significantly, that is, 11.8 4.5 versus 10.8 5.2
molIliter. When iron- and aluminum-loaded dogs received
desferrioxamine, a striking linear correlation was found be-
tween the serum tV2, AUC and the serum creatinine and
between the renal clearance of the in vivo formed aluminox-
amine and ferrioxamine and the reciprocal value of serum
creatinine (Table 4, Fig. 3). As indicated by the slopes of the
linear regression curves, serum t½, AUC and renal clearance of
aluminoxamine and ferrioxamine after desferrioxamine admin-
istration did not differ significantly. The cumulative biliary
excretion of aluminoxamine after administration of desferriox-
amine was unchanged when compared to that of dogs of group
I which received the aluminoxamine/ferrioxamine mixture (0.21
0.13 moL/0 to 24 hr vs. 0.19 0.21 molJ0 to 24 hr).
However, the biiary elimination of ferrioxamine significantly
increased (P = 0.0022; Fig. 4) and, in the renal failure group of
dogs (TIC-H; N = 6), approached or even exceeded the cumu-
lative renal excretion [mean SD (range) cumulative biliary
excretion 5.4 3.4 (1.2 to 9.0) moIJ0 to 24 hr vs. cumulative
urinary excretion 9.8 4.8 (0.5 to 13.1) xmol/0 to 24 hr].
Hepatic clearance of the in vivo formed ferrioxamine and
aluminoxamine was not affected by renal insufficiency (Fig. 3A,
B). After Lv. administration of a dose used in clinical medicine,
that is, 200mg (15.3 3.5 mg/kg) of desferrioxamine, 13 16%
of the administered desferrioxamine dose was recovered unche-
lated in the urine 24 hours after administration of the com-
pound, while only 1.1 0.7% of the initial desferrioxamine
Table 3. Hepatic and bone iron and aluminum concentrations in
aluminum- and iron-loaded dogs (Group II) versus unloaded dogs
(Group I)
0
0
0
0
.
+ 1.47
r= 0.9486
Data are means SD (range).
Table 4. Comparison of pharmacokinetic data of aluminoxamine
versus ferrioxamine after desferrioxamine administration (Group II)
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Fig. 3. Rena! (I •) and hepatic (0) clearance of ferrioxamine (A)
and aluminoxamine (B) in dogs with various renal functions after i.v.
administration of desferrioxamine.
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dose appeared in the bile. Between 2.7 and 11.0% and between
2.9 and 4.3% of the initial desferrioxamine dose was excreted in
the urine as aluminoxamine and ferrioxamine, respectively.
The Cmax level of aluminoxamine was correlated with both
the bone aluminum (r = 0.8215; P = 0.0204; N = 8) and the liver
aluminum content (r = 0.8337; P 0.0182; N = 8; Fig. 5).
Slopes of these linear regression curves differed significantly (P
= 0.0006). The Cm,, of ferrioxamine correlated with the liver
iron cont"t (r = 0.7410; P = 0.0358; N 8). No relationship
was noted between the Cm offerrioxamine and the bone iron
content (Fig. 5).
Discussion
Desferrioxamine has recently been introduced as a non-
invasive diagnostic tool and the only available therapeutic agent
for aluminum overload/toxicity in dialysis patients. In these
subjects, however, the potential for desferrioxamine, presum-
ably when chelated to iron, to predispose to infections or
aggravate their severity has repeatedly been reported [10, 11,
23, 24]. On the other hand, it has been speculated that the
aluminum chelated compound, that is, aluminoxamine by its
ability to cross the blood/brain barrier might precipitate or
exacerbate aluminum-related encephalopathy [8, 9, 25].
Prevention of these side effects during treatment of aluminum
and iron overload requires a solid knowledge of elimination
routes, distribution and sites of action of the chelator. In a
previous study in dialysis patients, we noted an inter-dialytic
decline in the serum ferrioxamine levels whereas the serum
aluminoxamine concentrations remained stable after desferri-
oxamine administration. Moreover, when compared to dialysis
patients with normal iron status we found that for ferrioxamine
both the serum t½ and the AUC were increased in hemosider-
otic dialysis patients, particularly when iron overload was
combined with liver disease. Since this phenomenon could not
be attributed to differences in residual renal function, the
contribution of a extrarenal (biiary ?) route for ferrioxamine
elimination was suggested.
To confirm our previous data and to determine the role of the
liver in the elimination of ferrioxamine and aluminoxamine in
the presence of either renal failure or intact renal function, the
pharmacokinetics of these compounds were studied in dogs
with normal renal function as well as in animals with various
degrees of renal insufficiency. Studies in the literature dealing
with these topics in humans [13, 14, 26, 27] and in animals
[28—31] are scarce. They have mostly been carried out using
methodology showing poor analytical performance [26, 32, 33]
and were incapable of determining aluminoxamine.
Data in the present study are based on a validated indirect
atomic absorption spectrometric method having great accuracy
and precision [12]. Its low detection limits and high sensitivity
were appropriate for the purpose of this study. The method was
found to be superior [12] to these described using high perfor-
mance liquid chromatography [34, 35], particularly in view of
complexity and risk for contamination.
A reduction in renal mass was induced in dogs according to
the method described by Vaneerdeweg et al [16]. All dogs
underwent a ligation and catheterization of the bile duct allow-
ing intermittent bile drainages during a three week period under
sterile conditions. Serum alkaline phosphatase and total and
direct biirubin determinations together with the histological
examination of liver biopsies [16, 18] revealed that the liver
function was kept intact after ligation of the common bile duct.
A comparable technique for bile collection in rats with normal
renal function has been used by La Russo and Fowler [36] and
Pippard, Johnson and Finch [281. In these animals, however,
repeated bile, urine and blood sampling is rather complex and
sample volumes are limited being inadequate for use in longi-
tudinal studies. The main advantages of the proposed dog
model include the induction of a stable chronic renal failure
allowing protracted biiary ligation/sampling in the absence of
any interference with the renal and hepatic functions. It is of
note that pharmacokinetic data reported in the present paper
were obtained in the conscious animal, keeping metabolic
functions intact.
After aluminoxamine and ferrioxamine administration, elim-
ination of these compounds was mainly related to the renal
function as indicated by the good correlation between the
reciprocal value of the serum creatinine concentration and the
renal clearance of these compounds.
Our results on the cumulative renal excretion of ferrioxamine
agree with those noted by others in humans [37—39] reporting
that approximately 50% of the 59iron-labeled ferrioxamine was
found in the urine 24 hours after i.v. administration of this
compound. These data are in contrast to those of Keberle [31],
who reported that dogs excreted 94% of 59iron-labeled ferriox-
amine in five hours, however, after i.v. injection of a very large
dose (100 mg/kg vs. 4.7 1.1 mg/kg in the present study). The
above contradictory results must be interpreted keeping in mind
the data of Allain et al [401 reporting the renal clearance of
ferrioxamine to be greater in subjects with hemochromatosis as
P=O.0022
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Fig. 4. Comparison of the cumulative biliary excretion over 24 hours of
ferrioxamine and aluminoxamine after i.v. administration of the com-
pounds and after desferrioxamine. Data are the mean SD of all dogs
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compared to those with normal iron status, possibly represent-
ing a saturation effect of the renal tubular reabsorption mecha-
nism of ferrioxamjne that is known to occur at low concentra-
tions of the compound in animals [29, 41]. Our results showing
the renal clearance of the non-protein bound drugs aluminox-
amine and ferrioxamine in dogs with normal renal function to be
lower than the GFR, and the observation that the renal clear-
ance was lower at lower Cmax levels as noted in dogs of group
II versus those of group I, suggest the possibility of a saturable
tubular reabsorption mechanism that, however, needs further
investigation.
No data are available in the literature which deal with the
renal excretion of aluminoxamine. Our data on the cumulative
renal excretion and the renal clearance of this compound
indicate that, with respect to renal elimination and other phar-
macokinetic parameters (Table 2), aluminoxamine and ferriox-
amine behave in a similar fashion.
Only minute amounts of aluminoxamine and ferrioxamine
substances injected as such were eliminated via the bile,
demonstrating the negligible role of the liver in the elimination
of these compounds. Furthermore, we noted that the hepatic
clearance of aluminoxamine and ferrioxamine did not increase
in dogs with reduced renal mass as compared to those with
normal renal function.
A different situation exists when desferrioxamine was given
to dogs preloaded with iron and aluminum. Whereas the biiary
elimination of aluminoxamine did not change, ferrioxamine
concentrations significantly increased in the bile after desferri-
oxamine as compared to when the chelated compound itself
was administered. This is in agreement with data provided by
Hershko [42], and supports the concept that desferrioxamine
being a lipophilic molecule penetrates the liver cells resulting in
intrahepatic chelation of iron followed by biliary excretion of
ferrioxamine.
Although the liver represents an important storage site for
aluminum, intrahepatic chelation of the element by desferriox-
amine also appears to be limited. This suggests that chelation of
aluminum by desfemoxamine takes place at more accessible
sites such as the extracellular aluminum deposited at the
osteoid calcified bone boundary. The fact that the value of the
slope of the linear regression curve correlating Cm of alumi-
noxamine with the bone aluminum content is more than one
order of magnitude greater than that noted for the liver alumi-
num concentration supports this interpretation. Moreover, it
agrees with our unpublished observations in a dialysis patient
given a weekly desferrioxamine dose for six months, In this
subject, a remarkable decrease of the bone aluminum content
was noted with only a slight decrease in the hepatic aluminum
content.
Despite observations obtained in vitro which indicate that the
affinity of desferrioxamine for iron is nine orders of magnitude
greater than that for aluminum, the present data and other
observations [13, 26] show little difference in their affinity for
chelation by desferrioxamine in vivo based on the C,, of
ferrioxamine/Cmax of aluminoxamine ratio varying only be-
tween 0.8 and 1.7.
Our kinetic findings on the negligible biiary elimination of
aluminoxamine and ferrioxamine after administration of these
compounds are corroborated by the hydrophiicity of these
molecules which makes them unlikely to cross the hepatocyte
membrane. This is supported by our data showing that the
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relative distribution volumes of both aluminoxamine and fern-
oxamine are confined to the extracellular fluid. These observa-
tions confirm the inter-dialytic stability of the serum aluminox-
amine levels [131; however, they do not to any extent explain
the steady inter-dialytic decline of serum fernioxamine levels
after desferrioxamine administration previously noted in dialy-
sis patients, most of whom were without any renal function
[13]. The fact that the biliary excretion of fernioxamine after
administration of the compound as such was negligible suggests
the presence of an alternative mechanism in addition to the
renal elimination. Possibly, cellular assimilation of ferrioxamine
via an oxido/reductase mechanism by a specific ferrisidero-
phore receptor in close proximity of that described for trans-
fernin [43—45] might be responsible for this phenomenon. Once
transferrin, or in the actual situation ferrioxamine, is captured
by its receptor, iron release from the siderophore at the level of
the hepatocyte plasma membrane is thought to happen via
reduction of ferric iron to its ferrous state, resulting in destabi-
lization of the siderophore iron bond, liberating iron for cellular
uptake or release into the serum [44], and involving a decrease
of the serum ferrioxamine levels. The proposed mechanism is
based on enzymatic activity and thus is saturable. This might
explain the increased serum t½ of ferrioxamine in hemosider-
otic dialysis patients as compared to those with normal iron
status [13] and in nephrectomized dogs having received an
increased fernioxamine dose [29]. The hypothesis of a reductive
mechanism for the release of iron from ferrioxamine is also
supported by the in vitro observations of Emery [46] demon-
strating that under reducing conditions and in the presence of an
iron (2+) trapping agent the element can be displaced from
ferrioxamine. Aluminum (3+) cannot be reduced to a lower
valency state. Therefore, aluminoxamine, being chemically
similar to ferrioxamine, is not subject to reductive degradation,
which explains the stable inter-dialytic aluminoxamine levels in
dialysis patients.
Overall, the results of our study indicate that the dog is a
valuable model to study the renal and biliary elimination of
desferrioxamine and its chelated compounds. Renal clearance
of ferrioxamine and aluminoxamine is related to the renal
function. Both compounds are confined to the extracellular
space. Furthermore, biliary excretion of intravenously admin-
istered fernioxamine and aluminoxamine is negligible even in
renal failure. Our findings further provide indirect evidence that
desferrioxamine administration to iron- and aluminum-loaded
dogs results in the intrahepatic formation of ferrioxamine which
is partly excreted in the bile. Biliary excretion of aluminox-
amine after desferrioxamine administration however also is
negligible.
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